micvotabart pelidotin
micvotabart pelidotin: sourced relationships with 1 company · 2 clinical trials tracked.
micvotabart pelidotin evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could micvotabart pelidotin → PYXS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| Pyxis Oncology, Inc. (PYXS) Advanced Solid Tumors; Solid Tumor | Phase 1 |
| Pyxis Oncology, Inc. (PYXS) recurrent and metastatic head and neck squamous cell carcino… | Phase 1/Phase 2 |
Clinical Trial Registry Records (2)
A Phase 1/2, Open-label, Global, Multicenter, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Primary endpoint: Number of Participants who Experience a Dose-Limiting Toxicity (DLT)
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors
Primary endpoint: Number of Participants who Experience a Dose-limiting Toxicity (DLT) in Dose Escalation
Frequently asked questions
Which companies have sourced relationships with micvotabart pelidotin?
micvotabart pelidotin has dated SEC/FDA relationship records for Pyxis Oncology, Inc..
How many clinical trials involve micvotabart pelidotin?
BioSniper tracks 2 clinical trials involving micvotabart pelidotin.